

Date: 28th October, 2022

To,

BSE Limited

P. J. Towers, Dalal Street, Fort

Mumbai – 400 001

Ref.: BSE Scrip Code No. "533138"

Dear Sir / Madam,

National Stock Exchange of India Limited

Exchange Plaza, Bandra - Kurla Complex,

Bandra (East), Mumbai-400 051

Ref.: "ASTEC"

Sub.: Press Release

The Board of Directors of Astec LifeSciences Limited ("the Company"), at its Meeting held on Friday, 28th October, 2022, has approved the Unaudited Financial Results (both Standalone and Consolidated) as per Indian Accounting Standards (IND AS) for the Quarter and Half Year ended 30th September, 2022.

We enclose a copy of the Press Release and the same is being placed on the website of the Company, viz., www.astecls.com.

Please take the above information on your records.

Thanking you,

Yours sincerely,

For Astec LifeSciences Limited

Tejashree Pradhan Company Secretary & Compliance Officer (FCS 7167)

Encl.: As above











• Q2FY23 consolidated total income increased by 96.9% year-on-year

• Q2FY23 consolidated EBITDA grew by 69.5% year-on-year, EBITDA margin stood at 18.3%

• Q2FY23 Profit after tax grew by 101.8% year-on-year

• H1FY23 consolidated total income increased by 67.7% year-on-year

• H1FY23 consolidated EBITDA grew by 37.9% year-on-year, EBITDA margin stood at 16.7%

• H1FY23 Profit after tax grew by 34.7% year-on-year

•

•

•

•

•

•

•

•

		 _	

nts' om ons it in India and overseas, tax laws, import duties, litigation and labour relations